MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) saw its stock soar by 200% following the announcement of a remarkable cancer remission ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

MiNK Therapeutics stock surged 213% in premarket trading following the publication of a landmark case study showing complete ...

MiNK Therapeutics shares soared after the company published a case in a scientific journal of a cancer patient achieving remission after being treated with the company's cell therapy. Shares of the ...

Oncogene proteins articles from across Nature Portfolio Oncogene proteins are proteins encoded by oncogenes (dysregulated or activated genes) and have a potential to cause cancer. Transcription ...

Cancer does not develop overnight. It can take decades for cancer‐promoting changes in the genome to eventually lead to the ...

This review of oncogene-induced cell senescence describes a physiological mechanism that provides protection against cancer. The mechanisms underlying the arrest of growth in benign or premalignant ...

In the study, published in Nature Oncogene, a world-leading international team of scientists and clinicians explore the potential of necrosis -- when cells die unexpectedly as a result of ...

This review — the first in a series concerning the biology of cancer — is a comprehensive survey of oncogenes, tumor-suppressor genes, and microRNA genes in cancer cells. Work on the recently ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the ...